Brief Title
RCT of Ballon Technique VS Selective Ophthalmic Artery Infusion For the Retinoblastoma Patients
Official Title
RCT of Ballon Technique VS Selective Ophthalmic Artery Infusion For the Retinoblastoma Patients
Brief Summary
Retinoblastoma is the most common intraocular tumor in children..IAC--Targeted Treatment for Intraocular Retinoblastoma,Is minimally invasive procedure that infuse chemotherapy select into the ophthalmic artery, its can increasing the drug concentration reaching the tumor and reducing systemic toxicity compared with traditional intravenous treatment.: one is Ballon technique , another is selective ophthalmic artery infusion.This study evaluates the difference of Ballon technique and selective ophthalmic artery infusion effect in the treatment of retinoblastoma. Half of participants will receive, Ballon technique while the other half will receive selective ophthalmic artery infusion
Detailed Description
Delivering the chemotherapeutic agent in the arterial system through the ophthalmic artery transforms the treatment of retinoblastoma from systemic chemotherapy to local chemotherapy. Two alternative means can be used,The purpose of this study is to show that Ballon technique and SOAI delivered directly through the artery supplying the eye (ophthalmic artery) to patients with retinoblastoma is a safe and effective treatment.
Study Type
Interventional
Primary Outcome
Globe salvage rate (Eyes saved/Eyes treated)
Secondary Outcome
Visual pathway function
Condition
Retinoblastoma
Intervention
Ballon Technique
Study Arms / Comparison Groups
Ballon Technique group
Description: Intervention:Ballon Technique
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Device
Estimated Enrollment
496
Start Date
March 2018
Completion Date
December 2020
Primary Completion Date
December 2019
Eligibility Criteria
Inclusion Criteria: 1. No age limit, no gender limit, monocular or binocular affected; 2. New diagnosed cases, without any previous treatment; 3. Clinical diagnosed as retinoblastoma, and in group C, D or E according to IIRC standard; Binocular affected with one eye enucleated; 4. Normal bone marrow function 5. Normal liver function 6. Normal kidney function 7. Normal coagulation function 8. To be willing to take part in the clinical trial and sign the informed consent form; 9. To be willing to have these tumor sites surgically removed and do the follow up accordingly. Exclusion Criteria: 1. Diagnosis is not clear; 2. With other sever ocular diseases (for example: neovascular glaucoma, iris neovascularization); 3. With sever systemic diseases, include abnormal liver or kidney function, abnormal routine blood test or coagulation function, congenital heart diseases and dysaudia; 4. Took part in other clinical study within 3 months; 5. Refuse to take part in this clinical study; 6. Is not willing to do the follow up accordingly or follow up less than 2 times.
Gender
All
Ages
1 Month - 10 Years
Accepts Healthy Volunteers
No
Contacts
huiming xia, 136262828465, [email protected]
Administrative Informations
NCT ID
NCT03439397
Organization ID
GZWACMC20180112
Responsible Party
Principal Investigator
Study Sponsor
Guangzhou Women and Children's Medical Center
Study Sponsor
huiming xia, Study Director, Guangzhou Women and Children's Medical Center
Verification Date
February 2018